MedPage Today (1/16, Jenkins) reports that an “expert review” suggests “giving long-term high doses of docosahexaenoic acid to carriers of the apolipoprotein E ε4 (APOE4) allele” prior to the “onset of Alzheimer’s disease (AD) dementia may reduce the risk for AD, or delay the onset of symptoms.” Although “the review of landmark observational and clinical trials that assessed supplementation with ω-3 fatty acids such as docosahexaenoic acid (DHA), revealed it was not beneficial in symptomatic AD, several observational and clinical trials of ω-3 supplementation in the pre-dementia stage of AD suggested it may slow early memory decline in APOE4 carriers, reported” the authors in JAMA Neurology.